Share
The SAGE Handbook of Healthcare
Edited by:
Other Titles in:
Health Care Management | Health, Education & Welfare Economics | Other Health Specialties
Health Care Management | Health, Education & Welfare Economics | Other Health Specialties
May 2008 | 752 pages | SAGE Publications Ltd
With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment in healthcare there is enormous interest in the commercial as well as the scientific aspects of today's healthcare industry.
The SAGE Handbook of Healthcare provides an authoritative analysis of the current (and anticipated) developments in the global healthcare industries. Providing a unique perspective that interfaces between the science and business aspects, it combines information on the latest scientific developments with applied, commercial business data from the global marketplace.
The Handbook focuses on the aspects of paramount importance in the healthcare sector:
- Pharmacoeconomics
- Pharmacogenomics
- Therapeutics
- Diagnostics
Areas covered include:
- The role of nanotechnology, genomics and cell therapy in medicine
- Diagnostics; Biomarkers and technological advances
- Case studies in oncology and cardiovascular and CNS therapeutics
PART ONE: PHARMACOECONOMICS
Medicare Part D
Changes in US Oncology Drug Reimbursement
Prospective Payment Systems
Off-label Prescribing
Pricing and Reimbursement Issues in Neurology
Authorized Generics
Pharmaceutical Pricing and Reimbursement in Canada
Contrasting European and US Patent Laws
The Changing Face of European Drug Registration
The Impact of Reference Pricing in Europe
Pharmaceutical Pricing, Reimbursement, and Prescribing in the United Kingdom
Pharmaceutical Pricing, Reimbursement, and Prescribing in Italy
Pharmaceutical Pricing, Reimbursement, and Prescribing in Spain
The Impact of German Reference Pricing on Statins
Opportunities and Challenges in the Japanese Market for Cancer Therapies
Cancer Therapies Face Increasing Reimbursement Pressures in Europe and Japan
The Pharmaceutical Pricing and Reimbursement Environment in China
Will Point of Care Come of Age by 2010?
PART TWO: PHARMACOGENOMICS
Has Genomics Failed to Deliver?
The Role of Pharmacogenomics in Personalized Medicine
Cell Therapy
Nanotechnology in Medicine
Clinical Proteomics
PART THREE: THERAPEUTICS
Oncology
Novel Strategies in Oncology Clinical Trials
Antitumor Biologics
Outlook for Cancer Vaccine Development
Advances Imminent in Antiangiogenesis Therapeutics
Discoveries and Challenges in Early-stage Apoptosis Drug Development
Chronic Lymphocytic Leukemia
CNS
Opportunities in the Pharmacotherapy of Addiction
Immunology
Prevention of Organ Transplant Rejection
Cardiovascular
Cardiovascular Drugs and Devices Market
Renin Inhibitors
Future of VLA-4 Antagonist Drugs and Implications for the Regulatory Process
Impact of Inhaled Insulin on the Insulin Market
Impact of the PROactive Study on the Treatment of Type 2 Diabetes
PART FOUR: DIAGNOSTICS
Integrating Diagnostics and Therapeutics for Targeted Therapies
Part 1: Optimizing the Comarketing Plan
Integrating Diagnostics and Therapeutics for Targeted Therapies
Part 2: The Importance of Calculating the Return on Investment
Emerging Diagnostic Markers in Alzheimer's Disease
How are Translational Medicine Biomarkers Impacting Industry?
Unlocking the Potential of Biomarkers in Targeted Oncology
From Bioterrorism to Predictive Medicine: New Applications of Salivary Diagnostics
